Cogent Biosciences, Inc. Common Stock (COGT) is a publicly traded Healthcare sector company. As of November 5, 2026, COGT trades at $29.99 with a market cap of $5.46B and a P/E ratio of -14.24. COGT moved -6.18% today. Year to date, COGT is -13.75%; over the trailing twelve months it is +104.91%. Its 52-week range spans $3.72 to $43.73. Analyst consensus is strong buy with an average price target of $54.88. Rallies surfaces COGT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cogent’s $111.43 million Q3 loss and three bezuclastinib FDA dates: Cogent Biosciences’ third-quarter net loss was $111.43 million, with operating expenses of $117.18 million; its $791.1 million in cash, cash equivalents and marketable securities is expected to fund operations into late 2028. The company expects potential FDA approval of bezuclastinib for GIST by November 30, 2026, NonAdvSM by December 30, 2026, and AdvSM by June 29, 2027.
| Metric | Value |
|---|---|
| Price | $29.99 |
| Market Cap | $5.46B |
| P/E Ratio | -14.24 |
| EPS | $-2.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $43.73 |
| 52-Week Low | $3.72 |
| Volume | 2.32M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-328.94M |
| Gross Margin | 0.00% |
9 analysts cover COGT: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $54.88.